Theranostic Advances in Vascular Malformations.

Abstract

Vascular malformations are subdivided into capillary, lymphatic, venous, arteriovenous, and mixed malformations, according to the type of affected vessels. Until a few years ago, treatment options were limited to sclerotherapy and/or surgery. Since, it has been demonstrated that the majority of vascular malformations are caused by inherited or somatic mutations in various genes. These mutations lead to hyperactivity of two major signaling pathways: the RAS/mitogen-activated protein kinase and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways. These discoveries paved the way for the development and testing of targeted molecular inhibitors as therapies for vascular anomalies via repurposing of anticancer drugs.

• Authors: Valérie Dekeuleneer, Emmanuel Seront, An Van Damme, Laurence M Boon, Miikka Vikkula
• Journal: The Journal of investigative dermatology (J Invest Dermatol) Vol. 140 Issue 4 Pg. 756-763 (04 2020) ISSN: 1523-1747 [Electronic] United States
• PMID: 32200879 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Topics

• Disease Management
• Humans
• Theranostic Nanomedicine (methods)
• Vascular Malformations (therapy)